top of page

From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers

Feb 24

He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.

Recent Posts

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more

State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Savills' Life Sciences Overview

bottom of page